1
|
Cydzik M, Abdul-Wahid A, Park S, Bourdeau A, Bowden K, Prodeus A, Kollara A, Brown TJ, Ringuette MJ, Gariépy J. Slow binding kinetics of secreted protein, acidic, rich in cysteine-VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis. FASEB J 2015; 29:3493-505. [PMID: 25921830 DOI: 10.1096/fj.15-271775] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 04/21/2015] [Indexed: 12/22/2022]
Abstract
VEGF-A (VEGF) drives angiogenesis through activation of downstream effectors to promote endothelial cell proliferation and migration. Although VEGF binds both VEGF receptor 1 (R1) and receptor 2 (R2), its proangiogenic effects are attributed to R2. Secreted protein, acidic, rich in cysteine (SPARC) is a matricellular glycoprotein thought to inhibit angiogenesis by preventing VEGF from activating R1, but not R2. Because R2 rather than R1 mediates proangiogenic activities of VEGF, the role of human SPARC in angiogenesis was reevaluated. We confirm that association of SPARC with VEGF inhibits VEGF-induced HUVEC adherence, motility, and proliferation in vitro and blocks VEGF-induced blood vessel formation ex vivo. SPARC decreases VEGF-induced phosphorylation of R2 and downstream effectors ERK, Akt, and p38 MAPK as shown by Western blot and/or phosphoflow analysis. Surface plasmon resonance indicates that SPARC binds slowly to VEGF (0.865 ± 0.02 × 10(4) M(-1) s(-1)) with a Kd of 150 nM, forming a stable complex that dissociates slowly (1.26 ± 0.003 × 10(-3) s(-1)). Only domain III of SPARC binds VEGF, exhibiting a 15-fold higher affinity than full-length SPARC. These findings support a model whereby SPARC regulates angiogenesis by sequestering VEGF, thus restricting the activation of R2 and the subsequent activation of downstream targets critical for endothelial cell functions.
Collapse
Affiliation(s)
- Marzena Cydzik
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Aws Abdul-Wahid
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Soyeon Park
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Annie Bourdeau
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Katherine Bowden
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Aaron Prodeus
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Alexandra Kollara
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Theodore J Brown
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Maurice J Ringuette
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| | - Jean Gariépy
- *Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Medical Biophysics and Pharmaceutical Sciences, Department of Cell & Systems Biology, Department of Immunology, and Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
| |
Collapse
|
4
|
Belcastro AN, Gilchrist JS, Scrubb JA, Arthur G. Calcium-supported calpain degradation rates for cardiac myofibrils in diabetes. Sulfhydryl and hydrophobic interactions. Mol Cell Biochem 1994; 135:51-60. [PMID: 7816056 DOI: 10.1007/bf00925960] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
OBJECTIVE The purpose was to investigate the calcium required for calpain-mediated degradation of selected cardiac myofibril proteins modified by diabetes, sulfhydryl (SH) and hydrophobic reagents. METHODS After 20 weeks of streptozotocin-induced (55 mg.kg-1) diabetes, calcium sensitive calpain (1.5 U.ml-1) degradation rates of purified cardiac myofibrillar proteins (1 mg.ml-1) were measured, in vitro, and compared to degradation rates for N-ethylmaleimide (NEM) and 2-p-toluidinylnapthalene-6-sulfonate (TNS) treated samples. RESULTS Diabetes (blood glucose of 550 +/- 32 mg.dl-1) reduced the yield of purified myofibrillar protein with minimal change in fibril protein composition. Total SH group reactivities (nmol.mg-1.30min) were 220 +/- 21, 163 +/- 17 and 156 +/- 24 for control, diabetic and NEM-treated (0.5 mM) myofibrils (p < or = 0.05). Calpain degradation rates were faster for all diabetic and SH modified myofibrillar proteins (p < or = 0.05), with a 45 and 35% reduction in the pCa50 for a 37 kDa protein of diabetic and NEM-treated fibril complexes. For control myofibrils, both 100 and 200 uM TNS, reduced calpain degradation rates to a similar extent for all substrate proteins. In contrast, diabetic and NEM-treated samples showed a further reduction in calpain degradation rates with increasing TNS from 100 to 200 uM. CONCLUSION Our results support the hypothesis that in diabetes the calcium requirements for calpain degradation rates are reduced and dependent upon sulfhydryl group status and Ca(2+)-induced hydrophobic interactions, implicating a 37 kDa myofbillar-complexed protein.
Collapse
Affiliation(s)
- A N Belcastro
- Laboratory of Cell Physiology and Exercise, University of British Columbia, Vancouver, Canada
| | | | | | | |
Collapse
|